8th International Neoantigen Summit 2025

2024 saw a wealth of clinical progression with Nouscom, CureVac, Transgene and other pioneering companies paving the way for neoantigen based vaccines and therapies to become tolerable, durable medicines to effectively treat cancer.

Ready to unite the global neoantigen community, the 8th International Neoantigen Summit 2025 returns to address key challenges in the discovery, translation and clinical development of safe and cost-effective neoantigen therapies and vaccines to attract investors and ultimately improve the health of patients.

Join neoantigen leaders from the likes of AstraZeneca, Geneos Therapeutics, Evaxion Biotech and many more at this end-to-end meeting, focusing on the development of durable, neoantigen cancer vaccines and cell therapies. With the potential to deliver safe, efficacious personalized or off-the-shelf therapeutic options to patients, this is your chance to collaborate and accelerate the translation of neoantigen-based therapies from discovery to clinical success.

Speakers: Daniela Kleine-Kohlbrecher, Project Director, Immuno-Oncology - Evaxion Biotech, Heather Shaw, Consultant Medical Oncologist - Swarm Oncology, Jian Yan, Vice President, Research and Discovery - Geneos Therapeutics, Jingwei Sun, Vice President of R and D - Grit Biotechnology, John Campbell, Chief Scientific Officer - Swarm Oncology, Jon Moore, Chief Scientific Officer - Epitopea, Katka Franke, Senior Director Cancer Antigen Discovery and Validation - CureVac, Luigi Aurisicchio, Chief Executive Officer - Neomatrix, Marie-Laure Santiago, Raber Chief Scientific Officer - Amal Therapeutics, Massimo Fantini, Director, Research and Development - Precision Biologics, Maurizio Ceppi, Chief Scientific Officer - Transgene, Morena D'Alise, Senior Vice President, Immunology - Nouscom, Nermeen Varawalla, Chief Medical Officer - Scancell, Ola Nilsson, Head Of Neoantigen Production, Development and Clinical Processing - NEOGAP Therapeutics, Olivier Lantz, Head of the Hospital Clinical Immunology Laboratory, Group Leader - Institut Curie, Peter Johannes Holst, Chief Scientific Officer - HERVolutions Therapeutics, Prasun Chakraborty, Chief Scientific Officer - Genevation, Reagan Jarvis, Chief Executive Officer - Anocca, Robbert Spaapen, Associate Director - AstraZeneca, Sarah Maguire, Chief Scientific Officer - AilseBio, Sebastian Klobuch, Medical Oncologist - The Netherlands Cancer Institute, Ulrike Gnad-Vogt, Senior Vice President, Clinical Development - CureVac, Vanesa Bol, Director, Vaccines Discovery Data Sciences - GSK, Yaohe Wang, Chief Executive Officer - VacV Biotherapeutics